Cencora Raises Full-Year Outlook on Strong Q1 Performance, OneOncology Acquisition
Healthcare distribution giant Cencora (NYSE: COR) kicked off its fiscal 2026 with robust growth, reporting a 12% increase in adjusted operating income and a 9% rise in adjusted EPS. Bolstered by the completion of its OneOncology acquisition and sustained strength in its U.S. specialty pharmaceuticals business, the company has raised its full-year guidance.